Osteoprotegerin (OPG) has been reported to be associated with various cancer types, including bladder carcinoma, gastric carcinoma, prostate cancer, multiple myeloma, and breast cancer [295]. This evidence concerns the gene TNFRSF11B and urinary bladder carcinoma.